2024's Most Important Urolithin A Studies

Urolithin A has become one of the most researched longevity molecules, capturing the attention of scientists and clinicians around the globe. Backed by over 15 years of groundbreaking research, this postbiotic compound has shown immense potential in supporting mitochondrial health, muscle function, and biological aging.

In 2024, the momentum continued to grow, logging 125 new studies published this year alone. These latest findings not only expand our understanding of its benefits but also highlight its versatility across different populations and health applications. As we wrap up the year, let’s explore the key discoveries from this year and what they mean for the future of health and longevity.

New Clinical Data

MitoImmune Trial

The MitoImmune trial is perhaps the most exciting study to be completed this year. Conducted in collaboration with the world-renowned Buck Institute for Research on Aging and the Georg-Speyer-Haus Institute for Tumor Biology and Experimental Therapy, this clinical study revealed Mitopure’s ability to “rewire” an aging immune system in healthy adults.

As humans age, we develop an imbalance in a type of immune cell called naive CD8-T cells, which work as potent first responders to foreign pathogens found in our body. This study demonstrated that taking 1000mg of Mitopure for 4 weeks was able to improve CD8 cell activity and number through its action on mitochondrial function.

Additionally inflammatory makers associated with “inflammaging” were significantly improved.

While this study has not yet been published, the data was presented at the leading US immunology conference - The American Association of Immunologists.

Athletic Performance

The Research and Development team at Timeline has led the way with clinical studies investigating the role of Mitopure in muscle health and aging. Given the robust safety and efficacy they’ve demonstrated, independent research labs are now conducting their own trials using our proprietary Urolithin A.

Recently, a team of researchers out of Beijing, China, published a paper showcasing the benefits of using Mitopure in healthy, young, resistance-trained athletes. The authors of this study found that supplementing with 1000 mg of Mitopure for 8 weeks resulted in significant improvements in muscle strength and endurance and improved markers of exercise-induced inflammation.

Read the study here.

Mitopure Softgels

Bestseller

4.4 · 2762 reviews

The simplest form of Mitopure

Buy now

Promising Pre-Clinical Data

Before conducting human clinical trials, scientists will study interventions in animal and cell models. While these results can not be directly translated to humans, they provide important evidence on the likely benefit for humans and pave the way for clinical trials. Here are a few of the most interesting pre-clinical trials published this past year.

Urolithin A Shows Promise for Brain Aging

Two preclinical trials published this year suggest Urolithin A may be able to support healthy brain aging.

Urolithin A and amyloid beta

The first looked at the accumulation of insoluble proteins, specifically amyloid beta (Aβ) plaques, which have been linked with the development of age-related neurodegenerative disease.

This study was designed to explore the relationship between Aβ and age-related protein insolubility in animal models. As part of the study protocol, the researchers used Urolithin A to induce mitophagy and observe its effect on mitochondrial function and Aβ accumulation. This is due in part to data that suggest Aβ disrupts mitochondrial function through loss of mitochondrial protein homeostasis.

In this study, Urolithin A was shown to alleviate Aβ toxicity in animal models, supporting its potential use in clinical trials for age-related cognitive decline.

Read the study here.

Improves animal models of Alzheimer’s Disease

A second study, published in the June 2024 issue of Alzheimer’s and dementia, demonstrated Urolithin A’s ability to improve learning, memory, and olfactory function in mouse models of Alzheimer's Disease. This study also demonstrated Urolithin A’s ability to reduce Aβ and tau proteins and markers of neuroinflammation.

Read the study here.

Urolithin A and Age-Related Hearing Loss

Age-related hearing loss (ARHL) affects millions worldwide, significantly impacting quality of life and communication, especially in older adults. As one of the most common age-related sensory declines, ARHL is linked to cognitive decline, social isolation, and decreased independence. With no current cure, finding ways to prevent or slow its progression is crucial.

Recognizing the role of mitochondrial decline in age-related hearing loss, researchers explored whether enhancing mitochondrial function with Urolithin A could positively influence this condition.

In this study, Urolithin A was tested on mouse models of age-related hearing loss, and the results were promising. The Urolithin A-treated mice showed improved auditory function, better mitochondrial DNA integrity, and increased energy production in the cochlea and auditory cortex, suggesting that Urolithin A helps maintain cellular energy and mitochondrial health.

These findings position Urolithin A as a potentially novel approach to fighting combat sensory decline as we age and maintaining hearing health through targeted mitochondrial support.

Read the study here.

Healing Eye Damage with Urolithin A

The corneal epithelium acts as a physical barrier, helping to protect the eye from bacteria and external elements. Its integrity and health rely heavily on its ability to heal quickly after injury. While the epithelium typically recovers from an injury efficiently, certain pathological conditions—such as severe dry eye and diabetes—can impair or delay this process.

A key factor in delayed healing is cell senescence, a state in which cells stop dividing and enter a state of permanent arrest. As these cells accumulate over time, they have been shown to drive delayed wound healing.

A new study explores how Urolithin A may help combat this process. Using a mouse model and human corneal epithelial cell cultures, researchers found that Urolithin A significantly promoted healing in the corneal epithelium and decreased the accumulation of senescent cells.

These findings suggest that Urolithin A could represent a promising new approach for treating conditions characterized by poor wound healing of the corneal epithelium. While the results are encouraging in animal models, further clinical studies are necessary to determine whether these benefits extend to humans as well.

Read the study here.

Looking Ahead to 2025

The year 2025 is set to further expand the growing body of evidence supporting Urolithin A's role in promoting healthy aging in humans. Leading research institutions worldwide have recognized Mitopure as the purest and most reliable form of Urolithin A and are partnering with Timeline to investigate its potential as an intervention in various areas of age-related decline. Here are a few of the clinical studies currently underway

• Glucose metabolism: The National Institutes of Aging is studying whether Mitopoure is able to improve insulin levels and other hormones related to glucose metabolism.
• Oxidative stress in prostate cancer: The National Cancer Institute is investigating Mitopure’s ability to improve markers of oxidative stress and inflammation in men diagnosed with prostate cancer.
• Muscle preservation in immobilized patients: This study, being conducted at McMasters University, is looking at the effect of high protein supplementation vs high protein plus Mitopure on muscle loss due to leg immobilization.

2024 was a monumental year for Urolithin A discoveries, and 2025 will no doubt continue to solidify Urolithin A's place as a leading molecule in the science of healthy aging, offering hope and transformative possibilities for people at every stage of life.

We take immense pride in contributing not only to high-quality scientific advancements but also to creating life-changing products like Mitopure®—designed to profoundly enhance people’s quality of life.